AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06031727 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG202
Description: Method of Administration: Once unilateral subretinal injection; The duration of the study is about 52 weeks for each subject including a 4 weeks screening period, enrollment/baseline visit, treatment visit and 48 weeks follow-up period.
Study NCT06322160 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Interview with individual participant will take place via online videoconferencing MS Teams
Study NCT03694158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: anti-IL4 receptor antagonist
Study NCT03694158 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Dupilumab (packaged/administered the same as the active drug)
Study NCT06529380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS ON
Description: Electrical stimulation of the nucleus accumbens.
Study NCT06529380 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DBS ON
Description: Electrical stimulation of the nucleus accumbens.
Study NCT06529380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS OFF
Description: DBS will remain OFF (on at 0V).
Study NCT06529380 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DBS OFF
Description: DBS will remain OFF (on at 0V).
Study NCT05887375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
Study NCT05887375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
Study NCT05887375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
Study NCT05887375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
Study NCT05887375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
Study NCT05400967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Description: Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Study NCT06536413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA) Dose 0
Description: Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses.
Study NCT06536413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA) Dose -1
Description: Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.
Study NCT06536413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA) Dose 1
Description: Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.
Study NCT05615922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
Study NCT05615922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word-Naming Activity
Description: During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.
Study NCT06026033 — intervention group
Intervention type: DRUG
Intervention: Desflurane induction
Description: Following tracheal intubation, the fresh gas flow will be set to 1 liters/minute, desflurane vaporizer will be set to maximum.
Study NCT06186050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot drink
Description: Drink containing 10g of beetroot powder in 250 mL cold tap water
Study NCT06186050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mio flavouring in 250 mL cold tap water. Trace amounts of sugar and sodium were added to match the content in the beetroot supplement
Study NCT06186050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Low-fat meal with cornflakes, greek yogurt, skim milk, and orange juice
Study NCT06114238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab AI
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI
Study NCT06114238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itepekimab PFS
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
Study NCT04638231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive messages
Description: Daily supportive messages via SMS or email
Study NCT04638231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive messages
Description: Daily supportive messages via SMS or email
Study NCT05375461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsules
Description: The dose of TQB3616 capsules is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
Study NCT05375461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB3616-matching placebo
Description: The dose of placebo is 180mg, taken orally on an empty stomach, once a day for 28 consecutive days as one treatment cycle.
Study NCT05375461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvestrin injection
Description: Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
Study NCT05375461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvestrin injection
Description: Fluvestrin injection was given at a fixed dose of 500mg on day 1, day 15 of the first treatment cycle and day 1 of each subsequent treatment cycle, and a treatment cycle of 28 days.
Study NCT05998018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pdSTIM System Therapy
Description: Stimulate the phrenic nerves in synchrony with inspiratory cycles of the ventilator which exercises the diaphragm
Study NCT05672784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GNB plus standard analgesia
Description: When patients are in supine position with a pillow under the popliteal fossa, we will target points next to superior medial, superior lateral, and inferior medial genicular arteries to block the superior medial, superior lateral, and inferior medial branches of genicular nerve. For identification, we will use color Doppler near the periosteal areas (the junctions of the epicondyle with the shafts of the femur and tibia, accordingly). using a 12 MHz linear transducer (XarioTM SSA-660A, Toshiba Medical Systems Corporation, Otawara, Japan) positioned parallel to the shaft of the long bones in the legs, the needle will be inserted ( in plane technique in the long-axis view) and a 2.5 mL of bupivacaine (5%) will be injected at each target points.standard analgesia will be given post-operativelly (paracetamol 1 gm/ three times a daily and meloxicam (15 mg)once a day)
Study NCT05672784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GNB plus IPACK block plus standard analgesia
Description: IPACK block will be done when the patients in supine position with the knee flexed in 45 degree. using a low frequency transducer at a depth of 3.5-4 cm positioned transversely, 2-3 cm above the patella and over the medial aspect of the knee, we will identify the distal part of the shaft of the femur and the popliteal artery with sliding the transducer proximally and distally (If the two femoral condyles appear first, proximal sliding of the probe, so the humps of the femoral condyles will disappeared and the flat metaphysis will appeared). With advancement of the needle in plane toward the space between the popliteal artery and the femur, 15 ml of bupivacaine 0.5% will be injected. The genicular nerve block will be done as in group G and standard analgesia will be given post-operative as in group G
Study NCT05672784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard analgesia (paracetamol and meloxicam)
Description: (paracetamol 1 gm 3 times a daily and meloxicam (15 mg) once aday.
Study NCT04889105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smart MOVE!
Description: Multi-component behavioral intervention of PAD consisting of:~1. guideline-directed HBET prescription~2. active behavioral coaching (via MOVE! program or other)~3. mobile health monitoring
Study NCT04889105 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General walking advice
Description: Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.
Study NCT04889105 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Performance evaluation
Description: Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include:~1. Provider and stakeholder interviews~2. PAD patient interviews~2) N-of-1 trials to refine the intervention
Study NCT06441500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily tooth brushing programme
Description: Implementing the toothpaste/toothbrushing scheme involving free daily toothbrushing to every 3 - 5-year old child attending nursery. Free distribution of toothpaste/toothbrush packs to every child every 3 months. Collection of routine monitoring data linked with national data sets from the previous survey regarding caries prevalence and risk factors.2.Monitor caries activity - net caries increment for initial, moderate, and extensive caries severity.
Study NCT06293703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB
Study NCT06293703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB
Study NCT05421507 — intervention group
Intervention type: RADIATION
Intervention: Radioactive Iodine-125 Seeds Implantation
Description: Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
Study NCT04968808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged in-hospital complete revascularization
Description: Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Study NCT04968808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization
Description: Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Study NCT05432856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating, nutrition education, and sedentary time reduction strategies
Description: 1. TRE: You will be asked to eating as much as you like but only within an 8-10 hour window and then do not eat, or fast by consuming only water, black coffee or tea without milk/sugar for a window of 16 hours per day. This protocol will be required for 5 or more days in a row each week.~2. Nutrition education and individualized recommendations: You will receive an assessment, and one-on-one education on healthy eating according to Canada's dietary guidelines, with individualized small goal each to improve your dietary habits.~3. Sedentary time reduction: Using the provided Fitbit wrist monitor, you will be asked to track and gradually increase your daily step counts, break up periods of inactivity, and try to incorporate ways to decrease sedentary behaviour in everyday life.
Study NCT05320432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: A low-level electrical current through the skin activates the descending inhibitory systems in the central nervous system.
Study NCT05320432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No current applied through pads.
Study NCT04931082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Capsule
Study NCT04931082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT05116384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: cryo energy via cryoballoon
Study NCT05116384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: cryo energy via cryoballoon
Study NCT05116384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: renal artery denervation
Description: RF energy delivery to multiple sites within each major renal artery
Study NCT04760613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: 600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
Study NCT04760613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical capsules containing placebo (taken daily by mouth)
Study NCT05735327 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: As this is an observational study, no intervention will be administered.
Study NCT06297083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut Oral Powder [PEANUT POWDER]
Description: Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
Study NCT06297083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Oral Powder [PEANUT POWDER]
Description: Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
Study NCT06297083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)
Description: Probiotic or placebo-probiotic given daily for 18 months
Study NCT06297083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic (LGG®, Lactobacillus Rhamnosus) or placebo probiotic (maltodextrin)
Description: Probiotic or placebo-probiotic given daily for 18 months
Study NCT06434116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality
Description: The virtual reality headset is a device that simulates a realistic, three-dimensional environment, allowing the patient to be totally immersed, so that they feel as if they are really present in a virtual world. This environment can be combined with hypnotic verbal support.~Virtual reality will be achieved using a virtual reality headset (GAMIDA®, Pico G2 4K, France) and audio headphones with noise reduction (Bose® Quiet Comfort 35 II, France). A tablet (Samsung® Galaxy Tab A 2019, 4G / Lenovo M8, France) equipped with Healthy Mind software will enable patients to enjoy a 360° visual and auditory 3D experience via a Bluetooth connection.
Study NCT05154773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kidney donation and transplant information made easy
Description: Same as arm description
Study NCT06283355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasal Microbiota Transplant (NMT)
Description: nasal microbiota transplant
Study NCT06283355 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile swab
Study NCT06108414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose rivaroxaban
Description: Rivaroxaban 15mg q.d. (The dose should be reduced to 10mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
Study NCT06108414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose rivaroxaban
Description: Rivaroxaban 20mg q.d. (The dose should be reduced to 15mg q.d. in the following special populations: 1. Creatinine clearance \<50 mL/min; 2. Body weight ≤60kg; 3. Age ≥80 years old)
Study NCT04929249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Study NCT06273774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral Tablet